Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells
Open Access
- 28 February 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 106 (6), 1214-1223
- https://doi.org/10.1038/bjc.2012.59
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Renal Accumulation of Biglycan and Lipid Retention Accelerates Diabetic NephropathyThe American Journal of Pathology, 2011
- Deficiency of Biglycan Causes Cardiac Fibroblasts to Differentiate into a Myofibroblast PhenotypePublished by Elsevier BV ,2011
- HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endotheliumBritish Journal of Cancer, 2011
- Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligandsNature, 2010
- Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant TumorsThe American Journal of Pathology, 2009
- Biglycan, a Danger Signal That Activates the NLRP3 Inflammasome via Toll-like and P2X ReceptorsPublished by Elsevier BV ,2009
- Vinculin controls focal adhesion formation by direct interactions with talin and actinThe Journal of cell biology, 2007
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood, 2007
- Molecular regulation of vessel maturationNature Medicine, 2003
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971